In this video from LabTV, shared in 2015, meet Preethi Vijayaraj, “a graduate student in the Gomperts Lab at UCLA”, who is focusing her research into finding a treatment for pulmonary fibrosis and other lung diseases. Learn more about pulmonary fibrosis: http://bit.ly/1VElTQA…
LabTV shared this video in late 2015, where you can meet Abdo Durra- a research assistant in the Gomperts Lab at UCLA. Durra wants to understand and treat lung diseases, his main purpose being to develop a research model for IPF. Learn more about pulmonary fibrosis: http://bit.ly/1VElTQA…
Researchers discovered that mice exposed to bleomycin — a common pulmonary fibrosis model — displayed more intense fibrotic activity if they lacked the signaling factor PTEN. The findings suggest that exploring the signaling pathway involving PTEN might offer new insights into disease mechanisms, and aid the search for new treatment…
1. 6 Non-Pharmacological Pulmonary Fibrosis Treatments According to PulmonaryFibrosis.org, there are several types of treatment options to help you with your pulmonary fibrosis. In this article, we’re focusing on bringing you non-pharmacological pulmonary fibrosis treatments. Read more about it: http://bit.ly/1SgrR74 2. …
Anyone can suffer from pulmonary fibrosis, but it’s more common among middle-aged and older adults. Each patient has an individualized experience with the disease, which means that it can progress faster in some patients than others. As the lung tissue becomes thicker, the lungs lose their ability to properly…
Hyaluronan synthase 2 (HAS2) deletion from fibrotic fibroblasts induces senescence (gradual deterioration) in the cells and fibrotic clearance in mouse models of lung fibrosis. The findings, reported in the study “Hyaluronan synthase 2 regulates fibroblast senescence in pulmonary fibrosis” and published in the journal Matrix Biology, suggest…
According to the Pulmonary Fibrosis Foundation, there are some questions you should always keep in mind to ask your health care provider, to help you understand more about your disease and how it will affect your daily life. The most important thing is that you…
Nintedanib (marketed as OFEV by Boehringer Ingelheim) has shown very good results in clinical trials in patients with idiopathic pulmonary fibrosis (IPF). Nevertheless, some patients still experience disease exacerbation when treated with the drug. A case study described the successful reinstallation of the drug after an exacerbation — raising hopes…
In this video from ManagingSOB, it is discussed how to strengthen the respiratory muscles with respiratory muscle exercises. Learn more about pulmonary fibrosis: http://bit.ly/1VElTQA Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis…
Galectin Therapeutics, Inc., announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application “Method for Treatment of Pulmonary Fibrosis” — number 13/999,389 — on its lead compound GR-MD-02. Galectin Therapeutics is currently developing carbohydrate-based therapies…
Get regular updates to your inbox.
